NYSE
41 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Sally E. Blount Reports Stock Sale
Director Sally E. Blount sold 2,600 shares of Abbott Laboratories common stock at a price of $129.66 on April 30, 2025.
NYSE
43 days, 0 hours ago 
ABT
Abbott Laboratories
8-K: Abbott Laboratories Announces Executive Vice President and General Counsel Hubert L. Allen's Retirement
Hubert L. Allen, Executive Vice President, General Counsel, and Secretary of Abbott Laboratories, has announced his plans to retire after a transition period.
NYSE
44 days, 0 hours ago 
ABT
Abbott Laboratories
10-Q: Abbott Laboratories Reports Q1 2025 Results: Sales and Earnings Increase
Abbott Laboratories announces increased net sales and earnings for the first quarter of 2025, driven by growth in Medical Devices, Established Pharmaceutical Products, and Nutritional Products.
Better than expected
 
NYSE
44 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director John G. Stratton Reports Changes in Beneficial Ownership
Director John G. Stratton reports acquisition and disposal of Abbott Laboratories common shares and restricted stock units.
NYSE
44 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Daniel J. Starks Reports Acquisition of Common Shares and Stock Options
Director Daniel J. Starks reports acquisition of Abbott Laboratories common shares and stock options through incentive programs and a trust.
NYSE
44 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Michael F. Roman Reports Acquisition of Common Shares
Director Michael F. Roman reports acquisition of 1,635 common shares of Abbott Laboratories through restricted stock units.
NYSE
44 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Michael O'Grady Reports Stock and Option Transactions
Director Michael O'Grady reports acquisition of restricted stock units and stock options in Abbott Laboratories.
NYSE
44 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Nancy McKinstry Reports Stock Award and Option Grant
Director Nancy McKinstry reports the acquisition of restricted stock units and a stock option grant from Abbott Laboratories on April 25, 2025.
NYSE
44 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Acquires Shares and Restricted Stock Units
Director Darren W. McDew acquired 1,635 common shares and restricted stock units in Abbott Laboratories on April 25, 2025.
NYSE
44 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Michelle Kumbier Reports Changes in Beneficial Ownership
Director Michelle Kumbier reports acquisition of restricted stock units and disposal of common shares in Abbott Laboratories.
NYSE
44 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Gonzalez Reports Acquisition of Restricted Stock Units
Director Patricia Paola Gonzalez reports the acquisition of restricted stock units in Abbott Laboratories under the 2017 Incentive Stock Program.
NYSE
44 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Sally E. Blount Reports Acquisition of Restricted Stock Units
Director Sally E. Blount reports acquisition of 1,635 restricted stock units in Abbott Laboratories under the 2017 Incentive Stock Program.
NYSE
44 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Babineaux-Fontenot Reports Stock Award and Disposal
Director Claire Babineaux-Fontenot reports acquisition of restricted stock units and disposal of common shares of Abbott Laboratories.
NYSE
44 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Alpern Receives Stock Award
Director Robert J. Alpern reports acquisition of 1,635 common shares of Abbott Laboratories through restricted stock units.
NYSE
46 days, 0 hours ago 
ABT
Abbott Laboratories
8-K: Abbott Laboratories Holds Annual Shareholder Meeting, Elects Board and Ratifies Auditors
Abbott Laboratories successfully held its Annual Meeting of Shareholders on April 25, 2025, electing its Board of Directors and ratifying Ernst & Young LLP as its auditors.
NYSE
58 days, 8 hours ago 
ABT
Abbott Laboratories
8-K: Abbott Laboratories Reports Strong First-Quarter 2025 Results, Reaffirms Full-Year Guidance
Abbott Laboratories announced positive first-quarter 2025 results, with sales growth and adjusted EPS exceeding expectations, and reaffirmed its full-year 2025 financial guidance.
Better than expected
 
NYSE
71 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Acquires Stock Equivalent Units
Director John G. Stratton acquired 277 stock equivalent units of Abbott Laboratories on March 31, 2025, as part of director fees credited to a grantor trust.
NYSE
71 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Michael F. Roman Reports Stock Equivalent Unit Acquisition
Director Michael F. Roman reports acquisition of stock equivalent units in Abbott Laboratories due to director fees.
NYSE
71 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Acquires Stock Equivalent Units
Patricia Paola Gonzalez, a director at Abbott Laboratories, acquired 248 stock equivalent units on March 31, 2025, as part of director fees credited to a grantor trust.
NYSE
71 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Acquires Stock Equivalent Units
Director Robert J. Alpern acquired 59 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.
NYSE
90 days, 20 hours ago 
ABT
Abbott Laboratories
DEFA14A: Abbott Laboratories Sets Date for 2025 Annual Shareholder Meeting
Abbott Laboratories announces its annual shareholder meeting to be held virtually on April 25, 2025, with key items including the election of directors, ratification of auditors, and an advisory vote on executive compensation.
NYSE
91 days, 0 hours ago 
ABT
Abbott Laboratories
DEF: Abbott Laboratories Outlines Director Nominees, Executive Compensation, and Corporate Governance Practices in 2025 Proxy Statement
Abbott Laboratories' 2025 proxy statement details the election of directors, executive compensation, corporate governance, and sustainability initiatives, highlighting strong shareholder returns and a commitment to long-term growth.
Better than expected
 
NYSE
97 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Lisa D. Earnhardt Reports Stock Option Exercise and Sale
Lisa D. Earnhardt, an Executive Vice President and Group President at Abbott Laboratories, reported exercising stock options and selling shares on March 6 and 7, 2025.
NYSE
100 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Andrea F. Wainer Reports Share Disposals
Retired EVP Andrea F. Wainer reports disposing of Abbott Laboratories shares on February 28, 2025, and March 3, 2025, following retirement.
NYSE
100 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Sells Shares
Eric Shroff, a Senior Vice President at Abbott Laboratories, sold 562 common shares at $138.17 on March 3, 2025.
NYSE
100 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Daniel Gesua Sive Salvadori Reports Stock Disposal
EVP and Group President of Abbott Laboratories, Daniel Gesua Sive Salvadori, reports disposing of 8,462 common shares to cover tax obligations.
NYSE
100 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Louis H. Morrone Reports Changes in Beneficial Ownership
Executive Vice President Louis H. Morrone reports the disposition of Abbott Laboratories common shares, including those withheld for tax obligations and shares sold on the market.
NYSE
100 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Mary K. Moreland Reports Stock Transactions
Executive Vice President Mary K. Moreland of Abbott Laboratories reports the disposition and acquisition of company stock, including shares sold to cover tax obligations.
NYSE
100 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories VP and Controller, John A. McCoy, Jr., Reports Stock Transactions
John A. McCoy, Jr., Vice President and Controller of Abbott Laboratories, reports the disposition and acquisition of company stock.
NYSE
100 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories CEO Robert B. Ford Reports Stock Disposal
Robert B. Ford, Chairman and CEO of Abbott Laboratories, reported the disposal of 31,651 common shares to cover tax obligations.
NYSE
100 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Lisa D. Earnhardt Reports Stock Disposal
Lisa D. Earnhardt, EVP and Group President at Abbott Laboratories, reported disposing of 8,322 common shares on February 28, 2025.
NYSE
100 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories EVP and CFO Philip P. Boudreau Reports Changes in Beneficial Ownership
Philip P. Boudreau, EVP and CFO of Abbott Laboratories, reports a disposition of 4,908 common shares to cover tax obligations, leaving a direct holding of 56,553 shares and an indirect holding of 360 shares through a Profit Sharing Trust.
NYSE
100 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Hubert L. Allen Reports Stock Disposal
Executive Vice President Hubert L. Allen of Abbott Laboratories reports disposing of 8,382 common shares to cover tax obligations.
NYSE
105 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Andrea F. Wainer Reports Stock and Option Awards
Executive Vice President Andrea F. Wainer reports acquisition of Abbott Laboratories stock and options under the company's incentive programs.
NYSE
105 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Acquires Shares and Stock Options
Daniel Gesua Sive Salvadori, Executive Vice President of Abbott Laboratories, reports acquisition of common shares and stock options.
NYSE
105 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Acquires Shares and Options
Louis H. Morrone, Executive Vice President of Abbott Laboratories, reports acquisition of shares and options, including a performance-based restricted stock award and employee stock options.
NYSE
105 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Acquires Shares and Options
Mary K. Moreland, Executive Vice President of Abbott Laboratories, reports acquisition of shares and options, including performance-based restricted stock and employee stock options.
NYSE
105 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories VP Acquires Shares and Options in Latest Filing
John A. McCoy, Jr., Vice President of Abbott Laboratories, reports acquisition of shares and options, including a performance-based restricted stock award, in a recent SEC filing.
NYSE
105 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories CEO Robert B. Ford Reports Stock Award and Option Grant
Abbott Laboratories CEO Robert B. Ford reports the acquisition of performance-based restricted stock and stock options, along with the disposition of shares held in a family trust.
NYSE
105 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Earnhardt Acquires Shares and Options
Executive Vice President Lisa D. Earnhardt acquired shares and options in Abbott Laboratories on February 25, 2025, according to a Form 4 filing.
NYSE
105 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Philip P. Boudreau Reports Changes in Beneficial Ownership
Executive Vice President Philip P. Boudreau reports acquisition and disposal of Abbott Laboratories shares and stock options.
NYSE
105 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Hubert L. Allen Reports Stock Award and Option Grant
Executive Vice President Hubert L. Allen reports the acquisition of Abbott Laboratories shares through a performance-based restricted stock award and an employee stock option grant.
NYSE
111 days, 23 hours ago 
ABT
Abbott Laboratories
10-K: Abbott Laboratories Reports Strong Growth in 2024, Driven by Medical Devices and Nutritional Products
Abbott Laboratories' 2024 10-K filing reveals revenue growth driven by Medical Devices, Established Pharmaceuticals, and Nutritional Products, despite a decline in COVID-19 testing-related sales.
Worse than expected
 
Delay expected
 
NYSE
125 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories CEO Robert Ford Executes Stock Option and Sells Shares
Abbott Laboratories CEO Robert Ford exercised stock options and sold a portion of the acquired shares on February 5, 2025.
NYSE
132 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Hubert L. Allen Reports Stock Transactions
Executive Vice President of Abbott Laboratories, Hubert L. Allen, exercised stock options and sold shares on January 29th and 30th, 2025.
NYSE
132 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Exercises Stock Options and Sells Shares
Daniel Gesua Sive Salvadori, an Executive Vice President at Abbott Laboratories, exercised stock options and sold a portion of the acquired shares on January 30, 2025.
NYSE
133 days, 19 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Sells Shares
Executive Vice President of Abbott Laboratories, Louis H. Morrone, sold 2,644 common shares on January 28, 2025.
NYSE
142 days, 8 hours ago 
ABT
Abbott Laboratories
8-K: Abbott Reports Strong Q4 and Full-Year 2024 Results, Issues Optimistic 2025 Outlook
Abbott announced robust fourth-quarter and full-year 2024 results, exceeding initial guidance and projecting strong growth for 2025.
Better than expected
 
NYSE
160 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Acquires Stock Equivalent Units
Director John G. Stratton acquired 324 stock equivalent units of Abbott Laboratories on December 31, 2024, through director fees credited to a grantor trust.
NYSE
160 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Michael F. Roman Reports Stock Equivalent Unit Acquisition
Director Michael F. Roman reported the acquisition of 311 stock equivalent units in Abbott Laboratories on December 31, 2024, according to a Form 4 filing.
NYSE
160 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Patricia Paola Gonzalez Reports Acquisition of Stock Equivalent Units
Director Patricia Paola Gonzalez reports acquisition of 291 stock equivalent units in Abbott Laboratories on December 31, 2024, through director fees credited to a grantor trust.
NYSE
160 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Robert J. Alpern Reports Acquisition of Stock Equivalent Units
Director Robert J. Alpern reports acquisition of 69 stock equivalent units in Abbott Laboratories on December 31, 2024, through director fees credited to a grantor trust.
NYSE
209 days, 23 hours ago 
ABT
Abbott Laboratories
8-K: Abbott Laboratories Extends Change in Control Agreements with Executive Officers
Abbott Laboratories has extended the terms of its Change in Control Agreements with named executive officers through December 31, 2026.
NYSE
224 days, 23 hours ago 
ABT
Abbott Laboratories
10-Q: Abbott Laboratories Reports Strong Third Quarter Growth Driven by Medical Devices
Abbott Laboratories' third-quarter results show a 7.4% increase in sales excluding foreign exchange impacts, driven by growth in medical devices and established pharmaceuticals, despite a decline in COVID-19 testing revenue.
Better than expected
 
NYSE
232 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Hubert L. Allen Reports Stock Transactions
Executive Vice President Hubert L. Allen of Abbott Laboratories reports the exercise of stock options and subsequent sale of shares on October 21, 2024.
NYSE
240 days, 8 hours ago 
ABT
Abbott Laboratories
8-K: Abbott Reports Strong Q3 2024 Results, Raises Full-Year EPS Guidance
Abbott's third-quarter results show strong sales growth, particularly in Medical Devices, leading to an increased full-year EPS guidance.
Better than expected
 
NYSE
254 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director John G. Stratton Reports Acquisition of Stock Equivalent Units
Director John G. Stratton reports acquisition of 322 stock equivalent units in Abbott Laboratories through director fees.
NYSE
254 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Michael F. Roman Reports Acquisition of Stock Equivalent Units
Director Michael F. Roman reports acquisition of Abbott Laboratories stock equivalent units through director fees.
NYSE
254 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Patricia Paola Gonzalez Reports Acquisition of Stock Equivalent Units
Director Patricia Paola Gonzalez reports acquisition of 289 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.
NYSE
254 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Robert J. Alpern Reports Stock Equivalent Unit Acquisition
Director Robert J. Alpern reports acquisition of 69 stock equivalent units in Abbott Laboratories on September 30, 2024, through director fees credited to a grantor trust.
NYSE
272 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories CEO Robert Ford Executes Stock Options and Sells Shares
Abbott Laboratories CEO Robert Ford exercised stock options and sold shares on September 12, 2024, according to a Form 4 filing with the SEC.
NYSE
281 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Reports Changes in Beneficial Ownership
Philip P. Boudreau, Executive Vice President of Abbott Laboratories, reports a transaction involving common shares on September 1, 2024.
NYSE
281 days, 20 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Vice President John A. McCoy, Jr. Reports Stock Transactions
John A. McCoy, Jr., a Vice President at Abbott Laboratories, reported the disposition of company stock to cover tax obligations and a sale of shares.
NYSE
317 days, 0 hours ago 
ABT
Abbott Laboratories
10-Q: Abbott Laboratories Reports Second Quarter 2024 Results, Driven by Medical Devices and Nutritional Growth
Abbott Laboratories' second quarter results show a 4% increase in sales, driven by strong performance in Medical Devices and Nutritional Products, despite a decline in COVID-19 testing revenue.
Worse than expected
 
NYSE
330 days, 8 hours ago 
ABT
Abbott Laboratories
8-K: Abbott Reports Strong Q2 2024 Results and Raises Full-Year Guidance
Abbott's second-quarter results show strong organic sales growth, particularly in Medical Devices, leading to an increase in full-year earnings guidance.
Better than expected
 
NYSE
345 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Reports Stock Disposals
Louis H. Morrone, Executive Vice President of Abbott Laboratories, reports the disposal of common shares to cover tax obligations.
NYSE
345 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director John G. Stratton Reports Acquisition of Stock Equivalent Units
Director John G. Stratton reports acquiring 353 stock equivalent units of Abbott Laboratories on June 30, 2024, at a price of $103.91 per unit.
NYSE
345 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Michael F. Roman Reports Stock Equivalent Unit Acquisition
Director Michael F. Roman reports acquisition of stock equivalent units in Abbott Laboratories due to director fees.
NYSE
345 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Patricia Paola Gonzalez Reports Acquisition of Stock Equivalent Units
Director Patricia Paola Gonzalez reports acquisition of 317 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.
NYSE
345 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Acquires Stock Equivalent Units
Director Robert J. Alpern acquired 75 stock equivalent units of Abbott Laboratories on June 30, 2024, through director fees credited to a grantor trust.
NYSE
394 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President, Robert E. Funck, Jr., Reports Stock Transactions
Robert E. Funck, Jr., Executive Vice President of Abbott Laboratories, reports the exercise of stock options and subsequent sale of shares on May 10, 2024.
NYSE
400 days, 23 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Executive Vice President Lisa D. Earnhardt Sells Shares
Lisa D. Earnhardt, Executive Vice President of Abbott Laboratories, sold 22,852 common shares at an average price of $106.2541 on May 7, 2024.
NYSE
407 days, 0 hours ago 
ABT
Abbott Laboratories
10-Q: Abbott Laboratories Reports First Quarter 2024 Results, Driven by Medical Devices Growth
Abbott Laboratories' first quarter 2024 results show a 2.2% increase in net sales, driven by strong performance in the Medical Devices segment, despite a decline in COVID-19 testing related sales.
Worse than expected
 
NYSE
408 days, 0 hours ago 
ABT
Abbott Laboratories
8-K: Abbott Laboratories Executive Vice President of Finance Announces Retirement
Robert E. Funck, Jr., Executive Vice President, Finance at Abbott Laboratories, will retire effective July 1, 2024, after 36 years of service.
NYSE
408 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director John G. Stratton Reports Changes in Beneficial Ownership
Director John G. Stratton reports acquisition and disposal of Abbott Laboratories common shares and restricted stock units.
NYSE
408 days, 21 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Daniel J. Starks Reports Stock and Option Awards
Director Daniel J. Starks reports acquisition of restricted stock units and stock options in Abbott Laboratories under the 2017 Incentive Stock Program.
NYSE
408 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Michael F. Roman Reports Acquisition of Restricted Stock Units
Director Michael F. Roman reports acquisition of 1,866 restricted stock units of Abbott Laboratories, convertible to common shares upon certain events.
NYSE
408 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Michael O'Grady Reports Stock and Option Awards
Director Michael O'Grady reports acquisition of restricted stock units and stock options in Abbott Laboratories under the 2017 Incentive Stock Program.
NYSE
408 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Nancy McKinstry Reports Acquisition of Shares and Stock Options
Director Nancy McKinstry reports acquisition of Abbott Laboratories common shares and stock options under the company's incentive stock program.
NYSE
408 days, 22 hours ago 
ABT
Abbott Laboratories
Form 4: Abbott Laboratories Director Acquires Shares Through Restricted Stock Units
Director Darren W. McDew acquired 1,866 common shares of Abbott Laboratories through restricted stock units on April 26, 2024.
ABT 
Abbott Laboratories 
NYSE

Form 4: Abbott Laboratories Executive Vice President Lisa D. Earnhardt Sells Shares

Sentiment:
 SEC Form 4 Filing
 8 May 2024 5:00 PM

Lisa D. Earnhardt, Executive Vice President of Abbott Laboratories, sold 22,852 common shares at an average price of $106.2541 on May 7, 2024.

Summary
  • On May 7, 2024, Lisa D. Earnhardt, an Executive Vice President at Abbott Laboratories, sold 22,852 common shares.
  • The shares were sold at a weighted average price of $106.2541.
  • The price range for the sales was between $106.08 and $106.39.
  • Following the transaction, Earnhardt directly owns 61,462 common shares of Abbott Laboratories.
Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of an executive selling shares, which doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives to periodically sell shares for personal financial management.

Key Dates
  • 05/07/2024: Date of transaction: Lisa D. Earnhardt sold Abbott Laboratories shares.
  • 05/08/2024: Date of signature for the SEC filing.
Keywords
ABT 
Abbott Laboratories 
NYSE
Sector: TBD
 
Filings with Classifications
Better than expected
30 April 2025 4:14 PM
Quarterly Report
  • Net sales and earnings increased year-over-year, indicating improved financial performance.
  • The gross profit margin improved, suggesting better cost management and pricing strategies.
  • Strong growth in key segments like Medical Devices and Established Pharmaceutical Products contributed to the positive results.
Better than expected
16 April 2025 7:36 AM
Earnings Release
  • The company's adjusted EPS of $1.09 exceeded expectations.
  • Organic sales growth of 6.9 percent surpassed previous forecasts.
  • The adjusted operating margin of 21.0 percent was higher than anticipated.
Better than expected
14 March 2025 4:07 PM
Proxy Statement
  • Abbott's TSR performance is above the peer group median on a one-year and five-year basis.
  • The company returned $5.1 billion to shareholders in 2024 and increased its dividend by 7.3% for 2025.
  • Abbott's 2030 Sustainability Plan aims to reach 3 billion people a year with its products and services.
Worse than expected
21 February 2025 4:07 PM
Annual Report
  • COVID-19 testing-related sales decreased significantly to $747 million in 2024 compared to $8.4 billion in 2022.
  • The Diagnostics segment saw a sales decrease of 3.9% in 2024 and 38.2% in 2023, excluding the impact of foreign exchange, driven by lower demand for COVID-19 tests.
Delay expected
21 February 2025 4:07 PM
Annual Report
  • There were no delays in Abbotts 2024 research and development activities that are expected to have a material impact on operations.
Better than expected
22 January 2025 7:13 AM
Quarterly Report
  • Abbott exceeded the upper end of its initial guidance for both organic sales growth and adjusted earnings per share for 2024.
  • The company's fourth-quarter sales growth and earnings per share growth were the highest of the year.
  • Abbott's 2025 outlook projects strong organic sales growth and improved profitability.
Better than expected
31 October 2024 5:14 PM
Quarterly Report
  • The company's net sales increased by 7.4% excluding foreign exchange impacts, exceeding expectations.
  • The medical devices segment showed strong growth, with a 13.6% increase in sales for the first nine months of 2024, excluding foreign exchange impacts.
  • The company's gross profit margin improved to 51.4% in the third quarter of 2024, indicating better profitability.
Better than expected
16 October 2024 7:37 AM
Quarterly Report
  • The company's results exceeded expectations, particularly in organic sales growth and Medical Devices performance.
  • The full-year EPS guidance was raised, indicating a positive outlook for the remainder of the year.
Worse than expected
31 July 2024 4:02 PM
Quarterly Report
  • Net earnings decreased in both the second quarter and the first six months of 2024 compared to the prior year.
  • The company recorded a $143 million loss on the sale of a non-core business.
  • Diagnostic Products sales decreased due to lower demand for COVID-19 tests.
Better than expected
18 July 2024 7:37 AM
Quarterly Report
  • Abbott's results were better than expected due to strong organic sales growth, particularly in the Medical Devices segment.
  • The company raised its full-year EPS guidance, indicating improved financial performance compared to previous expectations.
Worse than expected
2 May 2024 4:11 PM
Quarterly Report
  • Net earnings decreased from $1.318 billion to $1.225 billion compared to the same quarter last year.
  • Diagnostic Products sales decreased by 17.6% due to lower COVID-19 testing demand.
Better than expected
17 April 2024 7:36 AM
Quarterly Report
  • Abbott's results exceeded expectations due to strong organic growth in its base business and better than expected performance in the Medical Devices segment.
  • The company raised its full-year sales and EPS guidance, indicating confidence in future performance.

Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.